Person who experienced the adverse event (patient)
| Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 126862121 | 12686212 | 1 | I | 20160525 | 20160525 | 20160825 | 20160825 | PER | US-PERRIGO-16US016618 | PERRIGO | 33.92 | YR | F | Y | 0.00000 | 20160825 | CN | US | US |
Drug(s) used by person
| Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 126862121 | 12686212 | 1 | PS | NICOTINE POLACRILEX | NICOTINE | 1 | Buccal | 4 MG, EVERY 2 HOURS | U | 5LE1479 | 90711 | LOZENGE | |||||||
| 126862121 | 12686212 | 2 | SS | NICOTINE POLACRILEX | NICOTINE | 1 | Oral | 4 MG, SINGLE | U | 5LE1479 | 90711 | 4 | MG | LOZENGE |
Indications of drugs used
| Event ID | CASEID | INDI DRUG SEQ | INDI PT |
|---|---|---|---|
| 126862121 | 12686212 | 1 | Smoking cessation therapy |
| 126862121 | 12686212 | 2 | Accidental exposure to product |
Outcome of event
| no results found |
Reactions reported
| Event ID | CASEID | DRUG REC ACT | PT |
|---|---|---|---|
| 126862121 | 12686212 | Accidental exposure to product |
Reporting Sources (this data is often not reported and may therefore be missing here)
| no results found |
Therapies reported
| Event ID | CASEID | DSG DRUG SEQ | START DT | END DT | DUR | DUR COD |
|---|---|---|---|---|---|---|
| 126862121 | 12686212 | 2 | 20160525 | 20160525 | 0 |